SummitTX Capital’s Soleno Therapeutics SLNO Stock Holding History

SummitTX Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-56,585	Closed	-$1.89M	–	998
2026 Q1	$1.89M	Sell	56,585 -155,142	-73%	-$6.08M	0.06%	317
2025 Q4	$9.8M	Buy	211,727 +78,911	+59%	+$4.33M	0.3%	74
2025 Q3	$8.98M	Buy	132,816 +103,677	+356%	+$7.69M	0.37%	59
2025 Q2	$2.44M	Buy	29,139 +5,903	+25%	+$442K	0.11%	224
2025 Q1	$1.66M	Buy	+23,236	New	+$1.13M	0.07%	284

SummitTX Capital's SLNO Position: Q2 2026 in Review

SummitTX Capital sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 56,585 shares — an estimated $1.89M sold.

SummitTX Capital first reported a position in SLNO in Q1 2025 and held it in 5 quarters. The position peaked at $9.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

SummitTX Capital reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 56,585 Soleno Therapeutics shares in Q2 2026, an estimated $1.89M.
SummitTX Capital first reported a position in Soleno Therapeutics in Q1 2025 and held it in 5 quarters.
SummitTX Capital's Soleno Therapeutics position peaked at $9.8M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.